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Abstract
Clinical data indicate that prognostic stratification of radically resected colorectal cancer based on disease stage only may
not be always be adequate. Preclinical findings suggest that cancer stem cells may influence the biological behaviour of
colorectal cancer independently from stage: objective of the study was to assess whether a panel of stemness markers were
correlated with clinical outcome in resected stage II and III colon cancer patients. A panel of 66 markers of stemness were
analysed and thus patients were divided into two groups (A and B) with most patients clustering in a manner consistent
with different time to relapse by using a statistical algorithm. A total of 62 patients were analysed. Thirty-six (58%) relapsed
during the follow-up period (range 1.63–86.5 months). Twelve (19%) and 50 (81%) patients were allocated into group A and
B, respectively. A significantly different median relapse-free survival was observed between the 2 groups (22.18 vs 42.85
months, p = 0.0296). Among of all genes tested, those with the higher ‘‘weight’’ in determining different prognosis were
CD44, ALCAM, DTX2, HSPA9, CCNA2, PDX1, MYST1, COL1A1 and ABCG2. This analysis supports the idea that, other than
stage, biological variables, such as expression levels of colon cancer stem cell genes, may be relevant in determining an
increased risk of relapse in resected colorectal cancer patients.
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Introduction
Surgery remains the mainstay of treatment of non-metastatic
colorectal cancer patients and in about 50% stage III resected
patients, cure is achieved by surgery alone. Adjuvant treatment
trials such as the MOSAIC [1] or XELOXA trial [2] showed that
combination chemotherapy with 5FU/Capecitabine and Oxali-
platin yields a survival advantage in the ranges of 10–15% for
stage III resected patients.
In stage II patients, data are even more limited: adjuvant
chemotherapy is usually prescribed on the basis of risk factors or
‘‘the oncologist’s choice’’: the proportion of stage II patients
enrolled in clinical trials is too small to make definitive assumptions
regarding the benefit of adjuvant treatment in this subset of
patients [3–5].
To date the TNM staging system cathegories are the most
reliable way to address patients’ risk to relapse for decisions about
clinical management. A possible role for cancer stem cells has been
suggested as potential predictor of high risk of relapse in resected
colorectal cancer patients. These cells have been identified as
predictors of poor outcome and implied to have a role in cancer
progression and development of metastases, possibly as a
consequence of their hypothetical high replication potential [6,7].
Canonically, colorectal cancer stem cell population may be
primarily divided into 2 main classes: a typical subtype of
colorectal cancer stem cells, usually identified by CD133 positive
stain and a heterogeneous population of non-CD133 positive stem
cells. However both classes seem to possess an equally effective
capability to proliferate under certain conditions [8–10]. Due to
their biological characteristics cancer stem cells represent an
almost limitless resource for tumour growth and progression and
are thought to be responsible for maintaining a sort of protected
reserve niche for cancer cells. A further peculiarity of cancer stem
cells is their relative ability to escape chemotherapy-induced cell
death, thus reinforcing their role as a self-renewing cancer cells
source for tumours [11–13].
Based on these assumptions we can hypothesise that the cancer
stem cell population may be responsible for the biological
characteristics of tumour cells and may ultimately influence
clinical behaviour of solid tumours even during chemotherapy
treatment.
In a previous analysis of Gerger et al. [14] the Authors were
able to identify common cancer stem cell gene variants as
predictive factors for recurrence in radically resected colon cancer
patients. In this study germline polymorphisms of a limited
number of putative stem cells markers have been analysed.
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However it is possible that stem cell gene profile in tumours may
differ from what can be observed at the germline level. Moreover
stem cell gene expression in tumours may also be biologically
relevant.
In our study we assessed whether a panel of 66 genes, indicated
to have a role in growth and proliferation of colon cancer stem
cells, could allow to make a more accurate prediction of the
likelihood of relapse in resected non-metastatic colon cancer
patients. The final aim was to identify a stemness-based risk
category and to indicate possible stem cells-linked molecular
targets for future development of stem cell-directed treatment
strategies.
Materials and Methods
Patients Selection
Radically resected colon cancer patients receiving adjuvant
chemotherapy at our Department from 2005 to 2007 were
considered eligible for our study.
Patients should have presented either with a clinically defined
high risk stage II or with a stage III completely resected colon
tumour.
High risk stage II was defined in presence of at least one of the
following: pT4, poorly differentiated histology, bowel obstruction
or perforation at presentation, histologically proven vascular,
lymphatic or perineural invasion. We excluded from analysis
patients receiving adjuvant chemotherapy exclusively on the basis
of a non adequate lymph node sampling (lymph node sampling
less than 12).
Either single agent 5FU (or capecitabine) or 5FU (or
capecitabine) in combination with oxaliplatin were considered as
acceptable alternatives. Follow-up occurred according to Institu-
tional guidelines. History, physical examination, a complete blood
count, CEA and CA 19-9 determination were performed at three-
months intervals for three years, then at six months intervals at
years 4 and 5 after surgery. CT scan of chest and abdomen was
done every 6 months at year 1 through 3 and yearly thereafter at
years 4 and 5. Colonoscopy was performed at year 1 and then
every 3 and 5 years. The site and date of first relapse and the date
of death were recorded. For study purposes patients data were
retrospectively analysed. This study was approved by our
Institutional Ethical Committee (Comitato Etico Azienda Ospe-
daliera - Ospedali Riuniti, Ancona, Via Conca 71, Italy). All
patients gave their written consent to the study.
Samples Processing and Quantitative PCR Analysis
Gene expression profile analysis was performed by laboratory
personnel blinded to patients’ status.
Multiple sections of formalin-fixed, paraffin-embedded tissue
blocks (25 to 30 mg of primary tumour, manual microdissected
tissue) were collected; paraffin wax was removed and total RNA
was extracted by the RT2 FFPE RNA Extraction Kit (SABios-
ciences Corporation, Frederick, MD, USA), following the manu-
facturer’s instructions. RNA samples were quantified and quality-
tested for the presence of protein and/or organic solvent
contaminants by a spectrophotometric assay.
Five hundred nanograms from each sample were reverse
transcribed to cDNA and pre-amplified using the RT2 FFPE
PreAMP cDNA Synthesis Kit and the primer mix specific for the
customized Stem Cell RT2Profiler PCR Array (SABiosciences
Corporation).
Quantitative Real Time PCR analysis was performed on a 7300
Real-Time PCR System (Applied Biosystems Inc, Foster City, CA,
USA) by a SYBRH Green method. Target and reference genes
and controls selected for gene expression analysis came from the
Stem Cell genes set of the Stem Cells RT2Profiler PCR Array
(#CAPH09495-PAHS-405, SABiosciences Corporation). Also,
due to the lack in the standard PCR array of Stem Cell gene
markers more proper to colorectal cancer stem cells, the specific
genes ALCAM (also known as CD166), PROM1 (CD133), CD24
and LGR5 were added.
A complete list of the genes tested can be found in Table 1.
Data Processing and Statistical Analysis
Relative gene expression was quantified using the comparative
DCt method. We used the tool ‘‘PCR Array Data Analysis Web
Portal’’ (http://www.SABiosciences.com/pcrarraydataanalysis.
php) on the manufacturer’s website to perform data quality tests,
calculations on the qPCR data and data normalization. In
particular, all threshold cycles values greater than 35, or not
detected, were considered as negative calls. We retained samples
with negative genomic DNA control, definite reverse transcription
control and positive PCR control values, according to manufac-
turer’s indications.
To evaluate different patterns of gene expression, we conducted
clustering analysis by K-means (K = 2) method [15]. This
particular clustering analysis algorithm was chosen to test the
possible existence of 2 different patterns of gene expression, related
to different prognosis. In particular, the K-means method aims to
form pre-defined number (K) partitions into a cluster of different
observations in a data set, by the method of the nearest mean.
Clustering analyses were performed by MEV (MultiExperiment
Viewer) tool.
Statistical Analysis was Performed with MedCalc Package
(MedCalcH v9.4.2.0)
Primary endpoint of the study was to identify between the 2
prognostic groups a significant difference in median time to relapse
(TTR), calculated as the interval from the date of diagnosis to the
date of tumour recurrence. TTR was censored at the time of death
or last follow up if the patient had not recurred.
In the primary hypothesis that patients with resected high-risk
stage II-stage III colorectal cancer have around 60% relapse-free
risk at 2-years observation time and that patients with poor
prognostic score have 30% relapse-free risk at 2-years, assuming
alpha-probability error of 0.05 and beta-probability error of 0.10,
a minimum of 53 patients are needed to test the hypothesis.
The association between TTR and cancer stem cell genetic
profile was estimated by the Kaplan-Meier method. Significant
differences in probability of relapsing between the strata were
evaluated by log-rank test.
For each gene identified by K-means clustering analysis it was
subsequently evaluated the correlation with time to relapse: the
median of the overall specific gene concentration was used as cut-
off, due to lack of other more reliable and reproducible means to
estabilish a proper cut-off.
Results
A total of 62 patients were analysed. Among them, 36 had a
stage II colon cancer (58%) whereas the remaining 26 (41%) had a
stage III disease (table 2). Median follow-up period was 44 months
(range 12.5–86.5 months). During this follow-up period 36 (58%)
patients relapsed.
Among 26 stage III patients, 10 (38%) relapsed during the
follow-up period whereas in the remaining 36 stage II patients, 26
(72%) relapses were seen.
Colon Cancer Stem Cells and Risk of Relapse
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Table 1. Genes analysed and main gene function.
Stemness Markers
Cell Cycle Regulators APC AXIN1 CCNA2 CCND1 CCND2 CCNE1
CDC2 CDC42 EP300 FGF1 FGF2 FGF3
FGF4 MYC NOTCH2 PARD6A RB1
Chromosome and Chromatin Modulators GCN5L2 HDAC2 MYST1 MYST2 RB1 TERT.
Cell Division DHH NOTCH1 NOTCH2 NUMB PARD6A
Self-Renewal Markers HSPA9 MYST1 MYST2 NEUROG2 SOX1 SOX2
Cytokines and Growth Factors BMP1 BMP2 BMP3 CXCL12 FGF1 FGF2
FGF3 FGF4 GDF2 GDF3 IGF1 JAG1
Cell-Cell Communication DHH DLL1 GJA1 GJB1 GJB2 JAG1.
Cell Adhesion Molecules APC BGLAP CD4 CD44 CDH1 CDH2
COL9A1 CTNNA1 CXCL12 NCAM1
Metabolic Markers ABCG2 ALDH1A1 ALDH2 FGFR1
Stem Cell Differentiation Markers
Embryonic Cell Lineage Markers ACTC1 ASCL2 FOXA2 PDX1 ISL1 KRT15
MSX1 MYOD1 T
Hematopoietic Cell Lineage Markers CD3D CD4 CD8A CD8B MME
Mesenchymal Cell Lineage Markers ACAN ALPI BGLAP COL1A1 COL2A1 COL9A1
PPARG
Neural Cell Lineage Markers CD44 NCAM1 OPRS1 S100B TUBB3
Stem Cell Maintenance Pathways
Notch Pathway DLL1 DLL3 DTX1 DTX2 DVL1 EP300
GCN5L2 HDAC2 JAG1 NOTCH1 NOTCH2 NUMB
Wnt Pathway ADAR APC AXIN1 BTRC CCND1 FRAT1
FZD1 MYC PPARD WNT1
Cancer Stem Cells Markers ALCAM CD133 CD44 LGR5 SOX2 ALDH1A1
doi:10.1371/journal.pone.0072843.t001
Table 2. Patients characteristics.
Whole Group
(n=62) Group A Group B P value
Age (range) 64 (36–80) 65 (38–78) 64 (36–80) 0.95
Sex
Males 41 (66%) 8 (66%) 33 (66%) 0.76
Females 21 (37%) 4 (34%) 17 (34%)
Stage II 36 (58%) 10 (83%) 26 (52%) 0.09
- pT4a 11 (30%) 3 (25%) 8 (31%) 0.75
- Obstruction/Perforation 8 (22%) 3 (25%) 5 (19%) 0.36
- Vascular/Lymphatic/Perineural invasion 10 (28%) 4 (33%) 6 (23%) 0.17
- Poorly differentiated 13 (36%) 4 (33%) 10 (38%) 0.54
Stage III 26 (42%) 2 (17%) 24 (48%) 0.09
-pN1 20 (77%) 2 (100%) 18 (75%) 0.94
-pN2 6 (23%) 0 (0%) 6 (25%)
Treatment
- Fluoropyrimidines 28 (45%) 4 (33%) 17 (34%) 0.76
- Oxaliplatin combinations 34 (55%) 8 (67%) 33 (66%)
doi:10.1371/journal.pone.0072843.t002
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Median TTR for stage II patients was 23.3 months, whereas
median TTR was not reached for stage III patients. This
difference was not statistically significant (p = 0.0696).
When performing K-means analysis (K = 2), genes that had a
major role in determining allocation into one of the 2 pre-
determined groups were CD44 (p = 0.0004), ALCAM (p = 0.003),
DTX (p = 0.005), HSPA9 (p = 0.012), CCNA (p = 0.03), PDX1
(p = 0.04), MYST1 (p = 0.04), COL1A1 (p = 0.03), ABCG2
(p = 0.04). A comparison of the different means of expression of
these genes in group A and B can be found in Figure 1.
After clustering analysis two groups of patients were identified:
group A (unfavourable cancer stem cell gene profile) and group B
(favourable cancer stem cell gene profile).
Twelve patients (19%) were allocated by K-means analysis into
group A, whereas the remaining 50 patients (81%) were allocated
into group B. In group A, 2 stage III (17%) and 10 stage II (83%)
patients were allocated, whereas in group B the remaining 24
(48%) stage III and 26 (52%) stage II patients were allocated. All
the others clinical characteristics analysed resulted well balanced
between the 2 groups (table 2).
Eleven (91%) patients in group A relapsed during the
observation period whereas 25 (50%) patients in group B relapsed
during the same period. This difference was statistically significant
at the chi-square test (p = 0.0214). A significantly different median
TTR between the 2 groups was observed: 22.18 vs 42.85 months
(HR: 0.46, 95%CI: 0.15–090, p = 0.02) (Figure 2).
When analysing the impact of every single gene identified by K-
means analysis taken singularly, no significant relationship with
median TTR was observed. A summary of these results can be
found in Table 3.
Discussion
Identifying a subset of radically resected, non-metastatic
colorectal cancer patients who are at higher likelihood to relapse
has deep implications. TNM staging system, even if accounting for
tumour diffusion as the main factor influencing risk of relapse does
not account for biological characteristics of the tumour itself.
A possible role for cancer stem cells has been hypothesized as
potential predictor of high risk of relapse in resected colon cancer
patients [6–13]. These cells have been usually identified as
predictors of poor outcome and implied to have a role in cancer
progression and development of metastases. In our analysis we
suggested that cancer stem cell gene profile may be relevant in
determining TTR in high-risk stage II and stage III radically
resected colon tumours. Moreover the risk of relapse in our series
seemed not correlated with disease stage, suggesting that biology
more than stage guides natural history of colon cancer. When
performing K-means analysis (K = 2), genes who had a major role
in determining allocation into one of the 2 pre-determined groups
were CD44 (p = 0.0004), ALCAM (p = 0.003), DTX (p = 0.005),
HSPA9 (p = 0.012), CCNA (p = 0.03), PDX1 (p = 0.04), MYST1
(p = 0.04), COL1A1 (p = 0.03), ABCG2 (p = 0.04).
A role for CD44, ALCAM, DTX, HSPA9, CCNA, PDX1,
MYST1, COL1A1 and ABCG2 expression in influencing tumour
outcome, possibly through interaction with the stem cells
population, has been separately described in the past, but this is,
to our knowledge, the first time that multiple markers have been
examined simultaneously, confirming the relative significance of
each one of them.
However, among the molecular determinants emerged as
significant in our study, we believe that results regarding CD44,
ABCG2 and CD133 should be discussed further, especially
because of the biological peculiarity they possess.
In particular CD44 gene expression seemed to represent the
most important factor influencing the likelihood of relapse in our
group of resected patients. CD44 is also known as the receptor for
hyaluronic acid and has an important role in cells to stroma
interaction [16–19]. Although already reported as a predictive
factor for recurrence in colorectal cancer patients, substantial
controversy exists about the actual impact of different levels of
CD44 gene expression. In a previous work by Huang et al. [20]
stem cells taken from colorectal cancer patients were evaluated for
gene expression of CD44 and CD133 and tumours harbouring
higher levels of both CD44 and CD133 were related to higher risk
of development of early liver metastases.
On the contrary, in a work published by Dallas et al. [21] cells
that were engineered to be knock-down for CD44 expression had
almost 10 fold increase in metastatic potential in both liver and
lung. In addition to that, CD44 negative cells exhibited a greater
‘‘mechanical compliance’’ (the capacity for cytosol components to
move freely through the cytosol itself), a property that is
considered crucial in the process of extravasation and migration
through the blood-stream. Globally these findings seem to go
along with our observation that low levels of CD44 are relevant for
time to relapse in colon cancer.
On the contrary higher levels of expression of ABCG2 resulted
more frequently present in group A patients, those with worse
prognosis. ABCG2 (also known as CDw338) is a protein on the cell
surface, involved with transport of molecules across cell mem-
branes. Expression of this protein has been related with multi-drug
resistance and in a recent work of Oh et al. [22] colorectal cancer
Figure 1. Comparison of gene expression means between group A and B. Different gene expression means between patients with radically
resected colon cancer patients showing an unfavourable cancer stem cell gene profile, GROUP A, (red) and radically resected colon cancer patients
showing a favourable cancer stem cell gene profile, GROUP B (blue) as stratified by K-means (K = 2) method.
doi:10.1371/journal.pone.0072843.g001
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cells becoming resistant to FOLFOX chemotherapy exhibited
high levels of ABCG2. This could explain the apparent reduced
efficacy of adjuvant chemotherapy in our group of patients with
worse prognosis.
Even though published data so far seem to suggest that CD133
represents an important biomarker in colon cancer stem cells, its
role is far from being fully understood. This protein (also called
Prominin-1 or in abbreviated form PROM-1) has a role in the
formation of membrane protrusions and vescicular trafficking
[23]. Other than this rather base function, it is postulated that
PROM-1 interacts with other well-and-not-so-well known intra-
cellular messangers such as those involved in WNT/Beta-catenin,
PI3K-Akt-mTOR, HIF-1alfa and CXCR4 pathways [24,25].
In particular, high CD133 expression seems to be related to
worse prognosis in colorectal cancer due to its higher incidence in
metastases rather than in primary tumour [17].
In our analysis, different levels of CD133 were not linked to a
higher likelihood of relapse. Indeed, patients in group A and B had
heterogeneous levels of CD133 expression, with no significant
differences among the two groups. Also, when analysing the
impact of high vs low concentration of CD133 no significant
difference with TTR was observed.
These data seem to be in contrast with those presented by
Artells et al. [26] suggesting that high levels of CD133 gene
expression were correlated with a higher likelihood of relapse in
resected colorectal cancer patients. Our results may be explained
by the fact that in our analysis several different factors were taken
into account and not just one marker of stemness: due to the
nature of K-means analysis, in presence of multiple biological
factors with a more definite impact on TTR, the effect of CD133
as marker of relapse could be diluted.
We also know that CD133 IHC expression may be inducible
and that even previously CD133 null stem cells may express de novo
CD133 in different culture means and under specific conditions
Figure 2. Comparison of median time to relapse between group A and B. Kaplan-Meier curves for median time to relapse (TTR) of radically
resected colon cancer patients showing an unfavourable cancer stem cell gene profile, GROUP A (——) vs. radically resected colon cancer patients
showing a favourable cancer stem cell gene profile, GROUP B (-------) (22.1 months vs. 42.8 months, p = 0.02).
doi:10.1371/journal.pone.0072843.g002
Table 3. Impact of the genes identified by K-means analysis
and CD133 when analysed singularly and relapse risk and
time-to-relapse.
Gene
Relapse free survival
(Hi vs Low) HR (95%CI) p
CD44 33.24 vs 42.85 0.73 (0.29–1.86) 0.52
ALCAM 28.91 vs 42.00 0.59 (0.30–1.10) 0.09
DTX2 33.24 vs 42.03 0.90 (0.46–1.76) 0.76
HSPA9 39.01 vs 42.03 0.98 (0.50–1.90) 0.95
CCNA2 36.25 vs 42.03 0.72 (0.37–1.40) 0.33
PDX1 37.63 vs NR 0.68 (0.34–1.31) 0.25
MYST1 42.03 vs 39.01 0.78 (0.40–1.51) 0.46
COL1A1 39.01 vs NR 0.63 (0.32–1.22) 0.17
ABCG2 36.12 vs NR 0.31 (0.36–1.38) 0.71
CD133 42.85 vs 39.01 1.26 (0.50–3.23) 0.61
doi:10.1371/journal.pone.0072843.t003
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[27]. This could at least account for the contradicting results of
analysis conducted on CD133 IHC expression and prognosis.
Furthermore, in another experience of Shmelkov et al. [8]
CD133 null cells were hypothesised to possess even a more
aggressive phenotype than their counterpart CD133 positive. In
particular, when inoculated into SCIV mices, tumor growth from
CD133 negative stem cells was markedly greater than CD133
positive cell population.
Globally our findings suggest for the first time a potential role
for cancer stem cell gene profile in discriminating different risks of
relapse irrespectively of disease stage. These results may be also
relevant, after further confirmation, for the identification of
possible stem cells-linked molecular targets for future development
of stem cell-directed treatment strategies.
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